Bristol-Myers Squibb Company (BMY)
NYSE: BMY · IEX Real-Time Price · USD
42.64
+0.25 (0.59%)
At close: Jul 19, 2024, 4:00 PM
42.44
-0.20 (-0.47%)
Pre-market: Jul 22, 2024, 7:35 AM EDT
BMY Revenue
Bristol-Myers Squibb Company had revenue of $45.53B in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $11.87B with 4.66% year-over-year growth. In the year 2023, Bristol-Myers Squibb Company had annual revenue of $45.01B.
Revenue (ttm)
$45.53B
Revenue Growth
-0.68%
P/S Ratio
1.90
Revenue / Employee
$1,335,308
Employees
34,100
Market Cap
86.44B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
Dec 31, 2019 | 26.15B | 3.58B | 15.89% |
Dec 31, 2018 | 22.56B | 1.79B | 8.59% |
Dec 31, 2017 | 20.78B | 1.35B | 6.94% |
Dec 31, 2016 | 19.43B | 2.87B | 17.31% |
Dec 31, 2015 | 16.56B | 681.00M | 4.29% |
Dec 31, 2014 | 15.88B | -506.00M | -3.09% |
Dec 31, 2013 | 16.39B | -1.24B | -7.01% |
Dec 31, 2012 | 17.62B | -3.62B | -17.05% |
Dec 31, 2011 | 21.24B | 1.76B | 9.03% |
Dec 31, 2010 | 19.48B | 676.00M | 3.59% |
Dec 31, 2009 | 18.81B | 1.09B | 6.17% |
Dec 31, 2008 | 17.72B | 2.10B | 13.43% |
Dec 31, 2007 | 15.62B | -591.00M | -3.65% |
Dec 31, 2006 | 16.21B | -2.40B | -12.88% |
Dec 31, 2005 | 18.61B | -775.00M | -4.00% |
Dec 31, 2004 | 19.38B | 727.00M | 3.90% |
Dec 31, 2003 | 18.65B | 2.45B | 15.09% |
Dec 31, 2002 | 16.21B | -1.84B | -10.18% |
Dec 31, 2001 | 18.04B | 506.00M | 2.89% |
Dec 31, 2000 | 17.54B | 1.04B | 6.28% |
Dec 31, 1999 | 16.50B | 1.44B | 9.57% |
Dec 31, 1998 | 15.06B | -1.64B | -9.82% |
Dec 31, 1997 | 16.70B | 1.64B | 10.86% |
Dec 31, 1996 | 15.07B | 1.30B | 9.43% |
Dec 31, 1995 | 13.77B | 1.78B | 14.88% |
Dec 31, 1994 | 11.98B | 571.00M | 5.00% |
Dec 31, 1993 | 11.41B | 257.00M | 2.30% |
Dec 31, 1992 | 11.16B | 585.00M | 5.53% |
Dec 31, 1991 | 10.57B | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CVS Health | 360.94B |
McKesson | 308.95B |
Cigna | 206.00B |
HCA Healthcare | 66.72B |
GSK | 39.41B |
Medtronic | 32.36B |
Gilead Sciences | 27.45B |
Boston Scientific | 14.71B |
BMY News
- 3 days ago - Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma - Business Wire
- 4 days ago - Bristol-Myers Squibb Reports On 7/26 - Options Expire The Same Day - Forbes
- 14 days ago - Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day - Business Wire
- 20 days ago - Bristol Myers to pay $2.7 mln to settle Israel anti-competition charges - Reuters
- 25 days ago - Will Bristol Myers Squibb Stock Rebound To Its 2022 Highs Of $80? - Forbes
- 4 weeks ago - Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) - Business Wire
- 4 weeks ago - US FDA approves Bristol Myers' colorectal cancer therapy - Reuters
- 4 weeks ago - European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab - Business Wire